Skip to content

Serratus Anterior Plane Block Versus Serratus Posterior Superior Plane Intercostal Plane Block for Patients Undergoing Breast Surgery

Serratus Anterior Plane Block Versus Serratus Posterior Superior Plane Intercostal Plane Block for Patients Undergoing Breast Surgery

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06711549
Enrollment
46
Registered
2024-12-02
Start date
2024-11-20
Completion date
2026-11-01
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia, Breast Cancer, Mastectomy, Pain, Postoperative

Brief summary

The Serrato Posterosuperior Block (SPSIP) is a recently discovered technique that provides analgesia to the hemithorax, shoulders, neck and back. At an anatomical level, it has been seen that this technique allows the diffusion of local anesthetic starting from C7 proceeding dorsally up to T10 by sectioning the trapezius, latissimus dorsi, rhomboid and erector spinae muscles. The serratus anterior block (SAPB) is a technique that allows local anesthetic to be injected between the serratus anterior muscle and the intercostal muscles (deep plane) or between the latissimus dorsi muscle and the serratus anterior muscle (superficial plane), also providing analgesia at of the chest wall. This study aims to compare the analgesic efficacy of SPSIPB and SAPB in patients undergoing radical mastectomy for breast cancer

Interventions

PROCEDURESerratus Posterior Superior Plane Intercostal Plane block

Under ultrasound guidance; local anesthetic will be injected in the plane between the posterior aspect of the serratus posterior superior plane and the ribs

PROCEDURESerratus Anterior Plane block

Under ultrasound guidance; local anesthetic will be injected in the plane between the posterior aspect of the serratus anterior and the external intercostal muscles and ribs

Sponsors

Azienda Ulss 6 Euganea
CollaboratorOTHER
Ospedale di Camposampiero
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult Patient ( \> 18 years) * Informed consent * American Society of Anaesthesiologis Phisical Status I to III * Patients undergoing for mastectomy with sentinel lynphnode byopsy/axillary clearence

Exclusion criteria

* Pregnant women * Allergy to any drug present in the protocol

Design outcomes

Primary

MeasureTime frameDescription
Pain at 0 hours after surgery0 hours after surgeryThe primary objective of the study is to evaluate whether there is a difference between SAP block and SPSIP block at 0 hours after surgery at rest measure with visual analogic scale (0-10)

Secondary

MeasureTime frameDescription
Pain at 12 hours after surgery12 hours after surgeryEvaluate whether there is a difference between SAP block and SPSIP block at 12 hours after surgery at rest measure with visual analogic scale (0-10)
Pain at 24hours after surgery24 hours after surgeryEvaluate whether there is a difference between SAP block and SPSIP block at 24 hours after surgery at rest measure with visual analogic scale (0-10)
Pain at 6 hours after surgery6 hours after surgeryEvaluate whether there is a difference between SAP block and SPSIP block at 6 hours after surgery at rest measure with visual analogic scale (0-10)
Postoperative Opioid consumptionFrom extubation to 24 hours post-enrollmentPostoperative use of rescue analgesics (measured as yes or no)
Postoperative Nausea and VomitingFrom extubation to 24 hours post-enrollmentPostoperative Nausea and Vomiting defined as patient reporting nausea and vomiting or requiring drugs for nausea or vomiting
Intraoperative Opioid consumptionDuring the surgery(From patient intubation to patient extubation)Intraoperative opioids consumption (remifentanyl measured as mcg/kg)

Contacts

Primary ContactValentina Scaduto
valentinascaduto@yahoo.com3272217089

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026